<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020019</url>
  </required_header>
  <id_info>
    <org_study_id>#6015</org_study_id>
    <secondary_id>P50DA009236-16</secondary_id>
    <nct_id>NCT01020019</nct_id>
  </id_info>
  <brief_title>Combined Pharmacotherapy for Cannabis Dependency</brief_title>
  <acronym>D-LUCS</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Lofexidine in combination with Marinol is superior to
      placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in
      cannabis-dependent patients seeking treatment for their marijuana use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cannabis use disorders remain the most common illicit drug use disorder and options for
      treatment remain limited. Compared to other abusable substances, there has been little
      investigation of pharmacotherapies for cannabis dependence and no effective pharmacotherapy
      for cannabis dependence has yet to been developed. The development of effective cannabis
      dependence pharmacotherapy is an important unmet public health need. Agonist pharmacotherapy
      strategies have been effective for other substance use disorders (e.g., opioid and nicotine
      use disorders) and the endocannabinoid system represents a promising target for agonist
      pharmacotherapy with dronabinol. Lofexidine, a noradrenergic system suppressant, is effective
      in treating opioid withdrawal and shows promise as a cannabis use disorder pharmacotherapy.
      Haney et al. (2008) found that the combination of lofexidine and dronabinol (Lofex-Dro) was
      superior to placebo, lofexidine alone, or dronabinol alone in improving sleep and other
      cannabis withdrawal symptoms. Further, reduction in craving and relapse was greater for this
      combined pharmacotherapy relative to either medication alone or placebo. The proposed
      protocol is a 2 group, double blind, placebo-controlled outpatient study of the safety and
      efficacy of the combination of dronabinol and lofexidine for the treatment of cannabis
      dependence. We plan to enroll 180 subjects in a 12-week trial. The primary hypothesis is that
      dronabinol will act as an agonist treatment while lofexidine will suppress craving- and
      cue-induced related stress such that the combination will act in a complementary manner to
      induce prolonged abstinence from marijuana.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>21 Days of Consecutive Abstinence as Measured by the Time-line Followback.</measure>
    <time_frame>reported daily for 12 weeks/ or study participation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Cannabis Dependence</condition>
  <condition>Marijuana Dependence</condition>
  <arm_group>
    <arm_group_label>Lofexidine and Dronabinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lofex. matched placebo Dronabinol placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dronabinol</intervention_name>
    <description>Dronabinol: 20 mg/TID</description>
    <arm_group_label>Lofexidine and Dronabinol</arm_group_label>
    <other_name>Marinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lofexidine</intervention_name>
    <description>Lofex: .6 mg/ TID</description>
    <arm_group_label>Lofexidine and Dronabinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current marijuana
             dependence

          2. Individuals must report using marijuana at least 5 days a week and have a positive
             urine test for THC on the day of study entry.

          3. Individual must describe marijuana as their primary drug of abuse.

          4. Individuals must be capable of giving informed consent and capable of complying with
             study procedures.

        Exclusion Criteria:

          1. Meets DSM-IV-TR criteria for schizophrenia, schizoaffective illness, psychotic
             disorder other than transient psychosis due to drug abuse, major depression, bipolar
             illness or psychiatric disorders (other than substance abuse) which require
             psychiatric intervention.

          2. Individuals who are medically unstable based on laboratory tests, electrocardiogram,
             medical history, physical examination that would make participation hazardous

          3. Individuals with liver enzyme function tests greater than three times normal

          4. Individuals with a history of seizure disorder

          5. Individuals with current suicidal risk.

          6. Individuals who are cognitively impaired

          7. Bradycardia (&lt; 50 beats/minute), hypotension (sitting or standing BP &lt; 90/50), or
             symptoms attributable to low BP (i.e. lightheadedness or dizziness on standing).

          8. Nursing mothers and pregnant women. Women of child bearing age will be included in the
             study provided that they are not pregnant, based on the results of a blood pregnancy
             test drawn at the time of screening. They must also agree to use a method of
             contraception with proven efficacy and agree not to become pregnant during the study.
             To confirm this, urine pregnancy tests will be repeated monthly. Women will be
             provided a full explanation of the potential dangers of pregnancy while on the study
             medication. If a woman becomes pregnant, the study medication will be discontinued.

          9. Individuals who are physiologically dependent on any other drugs (excluding nicotine)
             that would require a medical intervention

         10. Individuals with known sensitivity to dronabinol or lofexidine

         11. Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG or history of cardiac symptoms

         12. Individuals currently being treated with an alpha-2 agonist antihypertensive
             medication

         13. Individuals currently being prescribed a psychotropic medication (including sleep
             medication). However, medication for depression is allowed if stable for at least 1
             month.

         14. Individuals who have a job that even mild intoxication would be hazardous (e.g.,
             firefighter, bus driver)

         15. Individuals who are court-mandated to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <results_first_submitted>April 6, 2016</results_first_submitted>
  <results_first_submitted_qc>April 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 11, 2016</results_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute on Drug Abuse (NIDA)</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Director of Substance Use Disorder</investigator_title>
  </responsible_party>
  <keyword>Cannabis Dependence</keyword>
  <keyword>Marijuana Dependence</keyword>
  <keyword>Marinol</keyword>
  <keyword>Lofexidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronabinol</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Lofexidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were treated at the Substance Treatment and Research Service (STARS) of Columbia University/ New York State Psychiatric Institute (NYSPI). Study enrollment occurred from January 2010 through May 2014 with study completion in September 2014.</recruitment_details>
      <pre_assignment_details>The study included a one-week placebo lead-in phase. Participants were randomized at the end of the placebo lead-in phase and those who reported marijuana use less than once a week during the lead-in phase were considered placebo responders and were not randomized. A total of 34 participants discontinued prior to randomization for various reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Lofex. matched placebo Dronabinol placebo
Placebo: Placebo control</description>
        </group>
        <group group_id="P2">
          <title>Lofexidine and Dronabinol</title>
          <description>Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not interested in treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>moving</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Lofex. matched placebo Dronabinol placebo
Placebo: Placebo control</description>
        </group>
        <group group_id="B2">
          <title>Lofexidine and Dronabinol</title>
          <description>Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="122"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="10.8"/>
                    <measurement group_id="B2" value="34.8" spread="11.2"/>
                    <measurement group_id="B3" value="35.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>21 Days of Consecutive Abstinence as Measured by the Time-line Followback.</title>
        <time_frame>reported daily for 12 weeks/ or study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Lofex. matched placebo Dronabinol placebo
Placebo: Placebo control</description>
          </group>
          <group group_id="O2">
            <title>Lofexidine and Dronabinol</title>
            <description>Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID</description>
          </group>
        </group_list>
        <measure>
          <title>21 Days of Consecutive Abstinence as Measured by the Time-line Followback.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of trial or participants length of participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Lofex. matched placebo Dronabinol placebo
Placebo: Placebo control</description>
        </group>
        <group group_id="E2">
          <title>Lofexidine and Dronabinol</title>
          <description>Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
Lofexidine and Dronabinol: Lofex: .6 mg/ TID Dronabinol: 20 mg/TID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>detoxification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>stomache upset</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>vomitting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>gas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>dizzy</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="61"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>intoxication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>sweating</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>orthostasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Brooks</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6171</phone>
      <email>brooksd@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

